The Phase 2a data1 from initial dosing cohorts marks the first robust demonstration of an oral OX2R agonist addressing wakefulness needs across NT1 patients, who lack endogenous orexin, and the ...
NEW Health dentists, Dr. Elodia Kore and Dr. Erika Omansky, are highly trained to deliver these cosmetic services with expertise and compassion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback